RISE Meta Model

Results

This meta-model represents the model used in Guzauskas GF, et al., 'Population Genomic Screening for Three Common Hereditary Conditions : A Cost-Effectiveness Analysis'. Ann Intern Med. 2023 May;176(5):585-595. doi: 10.7326/M22-0846. It is a regression of the probability sensitivity analysis data created via block selection using splines and interactions in R. The code is published at https://github.com/spgarbet/risesim .

Built using with the shiny package.

RISE Meta Model

Screening Assay Cost

Confirming Assay Cost

Lynch Variant Prevalence (%)

FH Variant Prevalence (%)

HBOC Variant Prevalence (%)

Relative Risk for MI FH(+), 190-220

No Test, Previous CVE proportion MI

Test Effect Size, Age 20-40

BC Mortality Relative Reduction: Early Stage

Utility Post Breast Cancer

BC Hazard Ratio Post-Oophorectomy: BRCA1

BC Hazard Ratio Post-Oophorectomy: BRCA2

Annual Intense Screening (MRI) Cost

Proportion of Known Carriers Who Get MRI

Stage A CRC Surveilled

Stage B CRC Surveilled

Stage C CRC Surveilled

Stage D CRC Surveilled

Stage A CRC Non-Surveilled

Stage B CRC Non-Surveilled

Stage C CRC Non-Surveilled

Stage D CRC Non-Surveilled

No Surveillance CRC Risk by 70, Males

Colonscopy Screening Cost/Yr

CRC Hazard Ratio Surveillance vs. None

Results